Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, child
Near ZIP Code:  within 100 miles of 20892
Results 1-13 of 13 for your search:
Start Over
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 8875, NCI-2013-01496, 110200, P11836, 11-C-0200, NCT01391962
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, CPZP034BUS1T, CPZP034BUS21T, MUSC 101644, MUSC CTO 101644, PAZ115785, PZP115785, NCT01593748
Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites
Status: Active
Phase: Phase II
Type: Treatment
Age: Greater than 3 to less than or equal to 40
Trial IDs: J1367, NCI-2013-02433, NA_00070109, NCT01763970
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Lorvotuzumab Mertansine in Treating Younger Patients with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1522, NCI-2015-00746, NCT02452554
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1?²5?T in HLA-A2+ Patients With Synovial Sarcoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 4 to 55
Trial IDs: ADP 04511, NCI-2015-00410, NCI-2013-01481, UPCC 04511, NCT01343043
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 50 and under
Trial IDs: D9902, NCI-2009-00502, CCG-B904, CDR0000078602, COG-D9902, IRS-D9902, POG-9153, NCT00919269
Collecting and Storing Tissue From Young Patients With Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 21 and under
Trial IDs: ABTR04B1, NCI-2009-00326, CDR0000478867, COG-ABTR04B1, NCT00898755
Gathering Information and Samples from Individuals at High Risk of Cancer Due to Li-Fraumeni Syndrome or Li-Fraumeni-Like Syndrome, or Who Have Adrenal Cortex or Choroid Plexus Carcinoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 3 and over
Trial IDs: 11-C-0255, NCI-2015-01243, 315309, P11858, NCT01443468
FLT PET in Predicting Malignant Tumors in Patients with Neurofibromatosis Type I
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 10 and over
Trial IDs: 14-C-0163, NCI-2014-02502, P141559, NCT02211768
Start Over